Ted Pharmaceuticals: Expected annual revenue to increase by approximately 25.5% to 32.3% in 2025.

Ted Pharmaceuticals announced on the Hong Kong Stock Exchange that it is expected that the revenue for the fiscal year ending on December 31, 2025 will be between approximately 555 million to 585 million yuan, an increase of about 25.5% to 32.3% compared to the previous year; the adjusted net profit will be between approximately 200 million to 230 million yuan, an increase of about 16.3% to 33.7% compared to the previous year. The company's board of directors believes that the growth in revenue is mainly due to the successful implementation of the molecular strategy, as well as the benefits of the company's integrated contract research, development, and production platform, industry-leading project delivery timeliness, excellent track record in project execution, and the continuing strong demand for the company's services from key customers.